Hypertension Treatment: Could Wider Access Save

What does the new hypertension analysis actually show?

Researchers modeled expanding preventive services to approximately 80% of eligible people. Blood pressure control produced the largest estimated mortality benefit among the services examined. The analysis defined control as below 140/90 mm Hg. Its findings were presented at the American Heart Association's October meeting. [AHA research report](https://newsroom.heart.org/news/managing-high-blood-pressure-could-prevent-500k-cvd-deaths-annually-in-20-countries).

The estimate depends on assumptions about treatment delivery and effectiveness. Some countries had limited underlying data, and the conference findings remain preliminary pending publication of a peer-reviewed manuscript.

The evidence that blood pressure medicines prevent cardiovascular events is stronger than this particular projection. A separate individual participant data meta-analysis published in The Lancet in 2021 examined randomized trials and supported pharmacological blood pressure reduction for preventing major cardiovascular events. That evidence supports treatment itself; it does not establish that health systems will achieve the coverage assumed by the new model. [Blood Pressure Lowering Treatment Trialists' Collaboration](https://pubmed.ncbi.nlm.nih.gov/33933205/).

Which blood pressure medicines could help close the treatment gap?

Common options include thiazide or thiazide-like diuretics, ACE inhibitors, angiotensin receptor blockers and long-acting calcium channel blockers. These medicines lower pressure through complementary mechanisms: diuretics help remove excess salt and water, while other classes relax blood vessels or reduce signals that constrict them. Examples include chlorthalidone, lisinopril, losartan and amlodipine. The choice depends on a person's other conditions and treatment needs. [WHO hypertension information](https://www.who.int/en/news-room/fact-sheets/detail/hypertension).

WHO's pharmacological treatment guideline supports initial combination therapy for adults who need medication, preferably using a single-pill combination to help people continue treatment consistently. Combining complementary medicines can reduce the number of tablets a person must manage. This recommendation applies to appropriately diagnosed, nonpregnant adults; it does not mean everyone should receive the same combination. Drug selection and dose adjustment still require clinical assessment. [WHO treatment recommendations](https://www.ncbi.nlm.nih.gov/books/NBK573627/).

What makes hypertension treatment effective and safe over time?

Effective treatment starts with reliable readings. NICE recommends validated devices, an appropriate cuff size and a quiet, seated measurement environment. Home or ambulatory monitoring can help confirm hypertension and clarify differences between clinic and everyday readings. Follow-up also needs to identify dizziness or falls that may signal a blood pressure drop on standing. These findings can change the appropriate treatment target or prompt a medication review. [NICE hypertension guidance](https://www.nice.org.uk/guidance/ng136/chapter/recommendations).

Medication works alongside measures such as reducing dietary salt, becoming more physically active and avoiding tobacco. WHO notes that many people still need medicines despite making these changes. For health services, its HEARTS approach combines treatment protocols, access to essential medicines, coordinated care and monitoring systems. The practical implication is that writing a prescription is one step in a continuing process: people also need dependable access to treatment and support when difficulties arise. [WHO hypertension information](https://www.who.int/en/news-room/fact-sheets/detail/hypertension).